Promising roles and current limitations of bortezomib-based desensitization for kidney transplantation.

Many transplant candidates show the presence of pre-formed antibodies against human leukocyte antigens (HLA), known as HLA sensitization, which poses a major immunological barrier to successful transplantation. Approximately 30%–40% of patients on the kidney transplant waiting list are sensitized to HLA

• Publication year

  2025

• Venue

  Kidney Research and Clinical Practice

• Publication date

  2025-09-30

• Fields of study

  Medicine

• Identifiers
  DOI 10.23876/j.krcp.25.159PMID 41035351PMCID PMC12990217
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Open-Label Phase 1/2 Study of Daratumumab-Based Desensitization Before Kidney Transplantation

  2024cited by this paper
• Reversing donor‐specific antibody responses and antibody‐mediated rejection with bortezomib and belatacept in mice and kidney transplant recipients

  2020cited by this paper
• Safety and efficacy of eculizumab in the prevention of antibody‐mediated rejection in living‐donor kidney transplant recipients requiring desensitization therapy: A randomized trial

  2019cited by this paper
• A prospective, iterative, adaptive trial of carfilzomib‐based desensitization

  2019influential reference
• IgG Endopeptidase in Highly Sensitized Patients Undergoing Transplantation.

  2017cited by this paper
• Desensitization Using Bortezomib and High-dose Immunoglobulin Increases Rate of Deceased Donor Kidney Transplantation

  2016cited by this paper
• The Impact of Proteasome Inhibition on Alloantibody-Producing Plasma Cells In Vivo

  2011cited by this paper

• No citing papers are available for this paper.